tetano
Editor, Senior Moderator
Virus Res. 2014 Oct 10. pii: S0168-1702(14)00409-2. doi: 10.1016/j.virusres.2014.09.018. [Epub ahead of print]
Incorporation of Conserved Nucleoprotein into Influenza Virus-Like Particles Could Provoke a Broad Protective Immune Response in BALB/c Mice and Chickens.
Xue C1, Tian G2, Chen X1, Liu Q1, Ma J1, Xu S1, Li X1, Chen H3, Cao Y4.
Author information
Abstract
We engineered influenza A/goose/GD/1996 (H5N1) (clade 0) virus-like particles (VLPs) by coinfecting Sf9 cells with triple/quadruple recombinant baculovirus that expressed hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1) with or without nucleoprotein (NP). VLP3 (HA, NA, and M1) and VLP4 (HA, NA, M1, and NP) vaccines (containing 1μg HA) with oil emulsion were administered to mice and chickens by intramuscular injection, and the immune responses were analyzed. The VLP-vaccinated mice demonstrated high antigen specific antibody titers and effective cellular immune responses. The mice and chickens vaccinated with VLP4 demonstrated more robust humoral and cellular immune responses than those vaccinated with VLP3. The VLP4 vaccine afforded 100% protection against a heterologous lethal influenza virus challenge (clade 2.3.4) whereas the VLP3 vaccine conferred 50% protection in chickens. These results implied that the incorporation of conserved NP protein into the VLPs could elicit a broad protective immune response in BALB/c mice and chickens. To the best of our knowledge, this study is the first report describing the immunological profile of the NP-containing VLPs vaccines in mice and chicken models, and the results demonstrate that the non-infectious, genome less VLPs, particularly those containing NP, represent a promising strategy for the development of a safe and effective vaccine to control pandemic influenza.
Copyright ? 2014. Published by Elsevier B.V.
KEYWORDS:
H5N1; Immune response; Nucleoprotein; Vaccine; Virus-like particles
PMID:
25312452
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25312452
Incorporation of Conserved Nucleoprotein into Influenza Virus-Like Particles Could Provoke a Broad Protective Immune Response in BALB/c Mice and Chickens.
Xue C1, Tian G2, Chen X1, Liu Q1, Ma J1, Xu S1, Li X1, Chen H3, Cao Y4.
Author information
Abstract
We engineered influenza A/goose/GD/1996 (H5N1) (clade 0) virus-like particles (VLPs) by coinfecting Sf9 cells with triple/quadruple recombinant baculovirus that expressed hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1) with or without nucleoprotein (NP). VLP3 (HA, NA, and M1) and VLP4 (HA, NA, M1, and NP) vaccines (containing 1μg HA) with oil emulsion were administered to mice and chickens by intramuscular injection, and the immune responses were analyzed. The VLP-vaccinated mice demonstrated high antigen specific antibody titers and effective cellular immune responses. The mice and chickens vaccinated with VLP4 demonstrated more robust humoral and cellular immune responses than those vaccinated with VLP3. The VLP4 vaccine afforded 100% protection against a heterologous lethal influenza virus challenge (clade 2.3.4) whereas the VLP3 vaccine conferred 50% protection in chickens. These results implied that the incorporation of conserved NP protein into the VLPs could elicit a broad protective immune response in BALB/c mice and chickens. To the best of our knowledge, this study is the first report describing the immunological profile of the NP-containing VLPs vaccines in mice and chicken models, and the results demonstrate that the non-infectious, genome less VLPs, particularly those containing NP, represent a promising strategy for the development of a safe and effective vaccine to control pandemic influenza.
Copyright ? 2014. Published by Elsevier B.V.
KEYWORDS:
H5N1; Immune response; Nucleoprotein; Vaccine; Virus-like particles
PMID:
25312452
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25312452